Yes, Gilead CEO Daniel O’Day is ready to ink some deals. No, you won’t see him sweat it
A bevy of analysts turned out for Gilead’s Q4 call Tuesday night looking for some of the old sizzle about the future that used to excite them in the past. What they got was a lecture on steady improvement, sound judgment and proper dealmaking — along with a plateful of slightly disappointing numbers that left more than a few feeling a bit deflated by the end.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.